Search

As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal

AS NOVARTIS BUYS IN TO GENE THERAPY, GSK BOWS OUT WITH ORCHARD DEAL

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn't yet seen commercial success. In...

 
 
 
Pulling the Plug on the First Gene Therapy Drug

PULLING THE PLUG ON THE FIRST GENE THERAPY DRUG

2017 is supposed to be the year that FDA finally approves a gene therapy. But last week, the company behind the first approved gene...